The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
Executes the first project for developing and manufacturing a novel anticancer mAb
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Additional capacity broadens Grace’s fine chemical capabilities for API production
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
Subscribe To Our Newsletter & Stay Updated
